文献速递胸部肿瘤

PD-L1免疫组化检测:分析性能与NSCLC临床应用综述

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2017-10-20

本综述总结2016年1月至2017年1月发表的PD-L1免疫组化检测研究,比较28-8、22C3、SP142、SP263等检测试剂在非小细胞肺癌中的分析性能与可比性。结果显示28-8、22C3和SP263在肿瘤细胞膜PD-L1表达评估中高度一致且重复性好,而SP142检测的PD-L1表达较低。免疫细胞PD-L1表达异质且观察者间一致性差。

要点

  • 28-8、22C3和SP263在肿瘤细胞膜PD-L1评估中高度一致,可能可以互换用于NSCLC。
  • SP142检测的肿瘤细胞PD-L1表达水平低于其他三种检测。
  • 免疫细胞PD-L1表达异质且观察者间一致性差,实验室自建检测一致性可变。

核心结论

  • 28-8、22C3和SP263在肿瘤细胞膜PD-L1表达评估中高度一致,提示其临床用于NSCLC可能可以互换,但不适用于免疫细胞PD-L1评估。
  • 实验室自建检测在推荐常规临床使用前需要严格标准化。

研究设计与样本

  • 综述分析2016年1月至2017年1月发表的临床试验及实验室自建PD-L1免疫组化检测研究。

主要发现

  • 28-8、22C3和SP263在肿瘤细胞膜PD-L1表达中显示高度一致性和观察者间重复性。
  • SP142检测的PD-L1表达较低。
  • 免疫细胞PD-L1表达可变且观察者间一致性差。
  • 肿瘤间和肿瘤内异质性对PD-L1表达影响不一。
  • 实验室自建检测之间一致性可变。

关键数值与推荐

  • 帕博利珠单抗治疗NSCLC需要PD-L1免疫组化检测;纳武利尤单抗和阿特珠单抗获批不要求PD-L1检测,但FDA已批准相应的补充诊断检测。
  • 临床试验中使用的PD-L1免疫组化检测包括28-8 pharmDx、22C3 pharmDx、SP142和SP263。

临床怎么用

  • 临床可参考28-8、22C3和SP263在肿瘤细胞膜PD-L1评估中的高度一致性。
  • 免疫细胞PD-L1评估因一致性问题需谨慎解读。
  • 实验室自建检测在常规使用前应严格标准化。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non-small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivolumab and atezolizumab are approved without PD-L1 testing, though US Food and Drug Administration-cleared complementary PD-L1 tests are available for both. PD-L1 IHC assays used to assess PD-L1 expression in patients treated with programmed death-1/PD-L1 inhibitors in clinical trials include PD-L1 IHC 28-8 pharmDx (28-8), PD-L1 IHC 22C3 pharmDx (22C3), Ventana PD-L1 SP142 (SP142), and Ventana PD-L1 SP263 (SP263). Differences in antibodies and IHC platforms have raised questions about comparability among these assays and their diagnostic use. This review provides practical information to help physicians and pathologists understand analytical features and comparability of various PD-L1 IHC assays and their diagnostic use. Methods We reviewed and summarized published or otherwise reported studies (January 2016 to January 2017) on clinical trial and laboratory-developed PD-L1 IHC assays (LDAs). Studies assessing the effect of diagnostic methods on PD-L1 expression levels were analyzed to address practical issues related to tissue samples used for testing. Results High concordance and interobserver reproducibility were observed with the 28-8, 22C3, and SP263 clinical trial assays for PD-L1 expression on tumor cell membranes, whereas lower PD-L1 expression was detected with SP142. Immune-cell PD-L1 expression was variable and interobserver concordance was poor. Inter- and intratumoral heterogeneity had variable effects on PD-L1 expression. Concordance among LDAs was variable. Conclusion High concordance among 28-8, 22C3, and SP263 when assessing PD-L1 expression on tumor cell membranes suggests possible interchangeability of their clinical use for NSCLC but not for assessment of PD-L1 expression on immune cells. Development of LDAs requires stringent standardization before their recommendation for routine clinical use.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Büttner R, Gosney JR, Skov BG, et al. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. J Clin Oncol. 2017. PMID: 29053400. doi:10.1200/JCO.2017.74.7642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。